Cisapride

Cisapride
Clinical data
Trade names	Prepulsid, Propulsid
AHFS/Drugs.com	FDA Professional Drug Information
MedlinePlus	a694006
Pregnancy; category	AU: B1; ;
Routes of; administration	By mouth (tablets), suspension
ATC code	A03FA02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); UK: POM (Prescription only); US: Withdrawn;
Pharmacokinetic data
Bioavailability	30-40%
Protein binding	97.5%
Metabolism	liver CYP3A4, intestinal
Elimination half-life	10 hours
Excretion	kidney, bile duct
Identifiers
	IUPAC name (±)-cis-4-amino-5-chloro-N-(1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl)-2-methoxybenzamide;
CAS Number	81098-60-4 ;
PubChem CID	2769;
IUPHAR/BPS	240;
DrugBank	DB00604 ;
ChemSpider	2667 ;
UNII	UVL329170W;
KEGG	D00274 ;
ChEMBL	ChEMBL1729 ;
CompTox Dashboard (EPA)	DTXSID3022825 ;
ECHA InfoCard	100.072.423
Chemical and physical data
Formula	C23H29ClFN3O4
Molar mass	465.95 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc1cc(c(OC)cc1N)C(=O)NC3CCN(CCCOc2ccc(F)cc2)CC3OC;
	InChI InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29) ; Key:DCSUBABJRXZOMT-UHFFFAOYSA-N ;
	(what is this?) (verify)

Cisapride is a gastroprokinetic agent, a drug that increases motility in the upper gastrointestinal tract. It acts directly as a serotonin 5-HT₄ receptor agonist and indirectly as a parasympathomimetic. Stimulation of the serotonin receptors increases acetylcholine release in the enteric nervous system. It has been sold under the trade names Prepulsid (Janssen-Ortho) and Propulsid (in the United States). It was discovered by Janssen Pharmaceuticals in 1980. In many countries, it has been either withdrawn from the market or had its indications limited due to incidence of serious cardiac side-effects.^[2] Propulsid was linked to children's deaths.^[3]

The commercial preparations of this drug are the racemic mixture of both enantiomers of the compound. The (+) enantiomer itself has the major pharmacologic effects and does not induce many of the detrimental side-effects of the mixture.^[4]

Medical uses

Cisapride has been used for the treatment of gastroesophageal reflux disease (GERD). There is no evidence it is effective for this use in children.^[5] It also increases gastric emptying in people with diabetic gastroparesis. Evidence for its use in constipation is not clear.^[6]

In many countries, it has been either withdrawn or had its indications limited because of reports of the side-effect long QT syndrome, which may cause arrhythmias. The U.S. Food and Drug Administration (FDA) issued a warning letter to doctors,^[7] and cisapride was voluntarily removed from the U.S. market on July 14, 2000. Its use in Europe has also been limited.^[5] It was banned in India and in the Philippines in 2011.^[8]

Veterinary uses

Cisapride is still available in the United States and Canada for use in animals, and is commonly prescribed by veterinarians to treat megacolon in cats.

Cisapride is also commonly used to treat GI stasis in rabbits, sometimes in conjunction with metoclopramide (Reglan).

Kinetics

Oral bioavailability of cisapride is approximately 33%. It is inactivated primarily by hepatic metabolism by CYP3A4 with a half-life of 10 hours. The dose of the drug should be reduced in case of liver diseases.^[9]

Pharmacology and mechanism of action

As a prokinetic agent that increases gastrointestinal motility, cisapride acts as a selective serotonin agonist in the 5-HT₄ receptor subtype. Cisapride also relieves constipation-like symptoms by indirectly stimulating the release of acetylcholine, which acts on muscarinic receptors.

References

^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
^ "Propulsid To Go Off Market - Warning". MedicineNet. Retrieved 2021-12-25.
^ "PROPULSID: A Heartburn Drug, Now Linked to Children's Deaths". Los Angeles Times. 2000-12-20. Retrieved 2021-12-25.
^ US patent 5955478, Gray NM, Young JW, "Methods for treating gastrointestinal motility dysfunction using optically pre (+) cisapride", issued 1999-Sep-21
^ ^a ^b Maclennan S, Augood C, Cash-Gibson L, Logan S, Gilbert RE (April 2010). "Cisapride treatment for gastro-oesophageal reflux in children" (PDF). The Cochrane Database of Systematic Reviews. 2010 (4): CD002300. doi:10.1002/14651858.CD002300.pub2. PMC 7138252. PMID 20393933.
^ Aboumarzouk OM, Agarwal T, Antakia R, Shariff U, Nelson RL (January 2011). "Cisapride for intestinal constipation". The Cochrane Database of Systematic Reviews (1): CD007780. doi:10.1002/14651858.CD007780.pub2. PMID 21249695.
^ ""Cardiac contraindications included in new FDA warnings about Propulsid"". medscape.com. January 25, 2000. Retrieved 10 May 2021.
^ "Drugs banned in India". Central Drugs Standard Control Organization, Dte.GHS, Ministry of Health and Family Welfare, Government of India. Archived from the original on 2015-02-21. Retrieved 2013-09-17.
^ Hedner T, Hedner J, Gelin-Friberg A, Huang ML, Van de Poel S, Woestenborghs R, Van Peer A, Heykants J (1990). "Comparative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers". European Journal of Clinical Pharmacology. 38 (6): 629–31. doi:10.1007/bf00278595. PMID 2373139. S2CID 33641651.

External links

Archived Drug Label

[1] Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.

[2] "Propulsid To Go Off Market - Warning". MedicineNet. Retrieved 2021-12-25.

[3] "PROPULSID: A Heartburn Drug, Now Linked to Children's Deaths". Los Angeles Times. 2000-12-20. Retrieved 2021-12-25.

[4] US patent 5955478, Gray NM, Young JW, "Methods for treating gastrointestinal motility dysfunction using optically pre (+) cisapride", issued 1999-Sep-21

[GERD2010-5] Maclennan S, Augood C, Cash-Gibson L, Logan S, Gilbert RE (April 2010). "Cisapride treatment for gastro-oesophageal reflux in children" (PDF). The Cochrane Database of Systematic Reviews. 2010 (4): CD002300. doi:10.1002/14651858.CD002300.pub2. PMC 7138252. PMID 20393933.

[Cochrane2011-6] Aboumarzouk OM, Agarwal T, Antakia R, Shariff U, Nelson RL (January 2011). "Cisapride for intestinal constipation". The Cochrane Database of Systematic Reviews (1): CD007780. doi:10.1002/14651858.CD007780.pub2. PMID 21249695.

[7] ""Cardiac contraindications included in new FDA warnings about Propulsid"". medscape.com. January 25, 2000. Retrieved 10 May 2021.

[ban-8] "Drugs banned in India". Central Drugs Standard Control Organization, Dte.GHS, Ministry of Health and Family Welfare, Government of India. Archived from the original on 2015-02-21. Retrieved 2013-09-17.

[pmid2373139-9] Hedner T, Hedner J, Gelin-Friberg A, Huang ML, Van de Poel S, Woestenborghs R, Van Peer A, Heykants J (1990). "Comparative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers". European Journal of Clinical Pharmacology. 38 (6): 629–31. doi:10.1007/bf00278595. PMID 2373139. S2CID 33641651.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]